The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. - Wikidata - thesis-toulmin - TriplyDB

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.

http://www.wikidata.org/entity/Q33378965

about

Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients.Triple negative breast carcinoma is a prognostic factor in Taiwanese women.Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life.Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis.Predictors of recurrence in breast cancer subtypes with negative lymph node in a Chinese population.Clinicopathological Characteristics of Triple-negative Breast Cancers in the Northeast Region of Turkey Possible prognostic significance of p53, cyclin D1 and Ki-67 in the second primary malignancy of patients with double primary malignancies.Triple-negative breast carcinomas are a heterogeneous entity that differs between young and old patients Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women.Characteristics of triple-negative breast cancer Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer Triple negative breast cancers have a reduced expression of DNA repair genes A prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index.Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China.Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer.N-acetylglucosaminyl 1-phosphate transferase: an excellent target for developing new generation breast cancer therapeutic Outcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell death.N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.Potential of Diffusion-Weighted Imaging in the Characterization of Malignant, Benign, and Healthy Breast Tissues and Molecular Subtypes of Breast Cancer.Failure patterns and survival outcomes in triple negative breast cancer (TNBC): a 15 year comparison of 448 non-Hispanic black and white women.Systematic review of breast cancer biology in developing countries (part 2): asian subcontinent and South East Asia.Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma.Pharmacotherapy of triple-negative breast cancer.Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer.Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.Triple-negative breast cancer: unique biology and its management.Silibinin inhibits triple negative breast cancer cell motility by suppressing TGF-β2 expression.Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer.Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy.Triple-Negative Breast Cancer: A Comprehensive Study of Clinical, Histomorphological, and Immunohistochemical Features in Indian Patients.Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer.Lymphangiogenic characteristics of triple negativity in node-negative breast cancer.Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis.Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression.

P2860

Q28387216-CF27786A-16DE-447D-BFDB-000C809662E0 Q33394017-34BEAE22-D20F-4B6C-8215-9F72FD7BA37B Q33470042-E143CCB9-2B1E-4BA0-A54A-E5FA42B0C5A2 Q33699438-12B6B26A-43C8-49D1-862C-5E299E37E86D Q33703527-33751D51-3C5C-46E6-A6D7-251D1A6220E0 Q33751806-A78E695A-AEBA-4390-8E26-0175144F5FC4 Q33898517-C71F860C-B856-43F9-9E37-9AA63602CD05 Q33974020-5034D630-B984-429E-8B31-2343A26B26A0 Q34029063-86C9D50D-7784-4E4F-AFC0-C4BD53363802 Q34275213-65EBAD3D-4AD8-4AE0-BD6A-F4D0E9351F95 Q34421158-198E9B9D-B4A5-4D2F-89BF-62FF4BCCC3F1 Q34479003-6FF205E2-B108-4CDE-A3E8-F6088DB01CAB Q34582473-8DCAB14B-FFA1-4B36-8195-ABDAA3D88E76 Q34794035-F42396F8-9522-48B1-9E6B-C29BDBFB94AB Q35067947-A13AC6D5-5FC3-4372-9092-87FC90E88AEA Q35558914-F8F70E97-D6E1-4AC1-8928-0F9CA10060F6 Q35558988-DB81CF51-6013-43DF-A840-9409CF0C5154 Q35803370-39FF6454-03E3-4013-AA98-E4BE80948E2E Q35909551-C6943181-3BB2-4AF0-BAC0-572DDC10765C Q36092026-C4FB133D-5FDA-40B1-B6C7-A1EB2BD43752 Q36156434-952925C0-777D-4801-AFA0-0C91B3D944DC Q36306513-5D2AB100-0649-4414-9541-29FAD98E7B3E Q36421921-9F7EE46D-F081-4C8B-B659-A314574498F9 Q36925030-FB395B44-67A1-4D57-877A-DFD6310D5731 Q37017435-7C9FE9BB-E43A-4BAA-B09B-DB4CE0AC3988 Q37132779-4B8D6EF5-071D-47B5-9C38-2893354BF195 Q37280294-D49B3367-15E1-4CFA-BCAA-22812913548E Q37565645-3A4473B9-2528-451A-8809-4133435CA4EF Q37659713-D84D4E09-4DA8-4F37-8101-8860DB3CDFEF Q37690172-456A1FA7-5FD0-496B-8AEA-9E5C7204B8AE Q37788688-7CAD6398-A539-4BCB-BB10-A7D9005FC543 Q38785742-966E4145-F8CC-4185-89DB-3637EBCCCCF6 Q42461856-DF9FBE69-DFCC-467B-BA52-F433F661B47F Q42464923-4F14B7AE-FC7C-4F8F-998E-49A41BD55290 Q42498742-9092DB0D-1126-4E42-8BED-0EF68B0137BD Q43467428-AB36EFB5-2B51-46CC-AA65-6E708336ED5B Q45984042-D77D64CA-7F04-4043-BC43-90E9C41905CA Q46365334-9A3BF21D-F002-4930-885B-194960185B33 Q47154634-4470FBAB-6D58-4B16-B3E6-9FF0DB1ED6DE Q50658602-07195BFD-E950-4D69-935B-3608FEBC616E

P2860

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.

http://www.wikidata.org/entity/Q33378965

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

The clinicopathologic characte ...... n node-negative breast cancer.

@ast

The clinicopathologic characte ...... n node-negative breast cancer.

@en

type

label

The clinicopathologic characte ...... n node-negative breast cancer.

@ast

The clinicopathologic characte ...... n node-negative breast cancer.

@en

prefLabel

The clinicopathologic characte ...... n node-negative breast cancer.

@ast

The clinicopathologic characte ...... n node-negative breast cancer.

@en

P1433

Q33378965-1B8129A6-03F8-474C-A7B6-7B8BBA41E42F

P1476

Q33378965-365CEE27-456E-4117-BD88-0EA4ACFBC6FC

P2093

Q33378965-126032CC-342C-45E7-B56B-1D2A0A186B7F

Q33378965-134E3A4A-1D8A-47DA-A5F4-C3A3F1B6F269

Q33378965-5D69A29D-BBDE-400F-AB00-29E7E6117DBD

Q33378965-5E2061BF-09EF-4B12-805E-55A5B6805326

Q33378965-6F8F695A-5F55-4DCA-8877-3FE6D36F6D95

Q33378965-7BE321E4-2BFB-4225-B088-9E5D779905C4

Q33378965-BA3E2854-7519-4399-A0E3-908FA836C195

Q33378965-CF48D105-8A50-4ECB-ADE7-955FB8DA4F38

Q33378965-EFFBEE19-157E-4A56-A351-C8E78DFE1055

P2860

Q33378965-0320A8B1-A9DF-4EA1-A8DB-FF9FD626B7D7

Q33378965-09FCD53B-DF43-43F5-AB6E-056567BF756B

Q33378965-0ED54313-0CBA-4EAB-BAA4-5130798871E5

Q33378965-1B5BD43B-A0C0-4117-A82E-54B63ED24BE2

Q33378965-1C7CEF9D-06B5-465C-AC5D-F64522E45137

Q33378965-1EA6B7D3-3365-486B-95C1-57C363384894

Q33378965-24BBB7CD-15CC-4C5E-A930-2CD9652CB206

Q33378965-294C8DC2-632E-445A-A257-D9C0CD720DE9

Q33378965-2C0C0CA6-27D6-4FF7-A74A-AD159C1658BB

Q33378965-354291FA-4A93-418C-8B19-0DF148302671

P2888

Q33378965-AB61767F-E5A8-4556-876D-1283604920FD

P304

Q33378965-59C1CB62-8D26-4609-AE0D-52DFAA93EED2

P31

Q33378965-017A5910-E4F4-4175-BFAA-38858D429742

P356

Q33378965-470E60F9-C426-4278-B3FC-FD38A932A312

P407

Q33378965-298AC16D-EA24-48DC-A8F6-98B197C1AF2E

P478

Q33378965-278DB7B1-083D-4443-84D4-203936E68C32

P50

Q33378965-DC06085C-6FBD-454A-8827-204BECEDFA17

P577

Q33378965-AAB48C15-0345-4D49-A779-683BA3CFEC06

P5875

Q33378965-A1015DCB-CB85-4FD8-B56E-75083322387D

P6179

Q33378965-6A176025-B7C1-4E71-B7A3-E3579D15EA32

P698

Q33378965-16853A6D-3E3D-4F37-95E3-E3A69EE6B715

P932

Q33378965-887194DD-EA59-4470-91DD-F9143479A933

P356

1471-2407-8-307

P1433

P1476

The clinicopathologic characte ...... n node-negative breast cancer.

@en

P2093

Do-Youn Oh

http://www.w3.org/2001/XMLSchema#string

In Ae Park

http://www.w3.org/2001/XMLSchema#string

Jee Hyun Kim

http://www.w3.org/2001/XMLSchema#string

Jiyoung Rhee

http://www.w3.org/2001/XMLSchema#string

Sae-Won Han

http://www.w3.org/2001/XMLSchema#string

Seock-Ah Im

http://www.w3.org/2001/XMLSchema#string

Tae-You Kim

http://www.w3.org/2001/XMLSchema#string

Wonshik Han

http://www.w3.org/2001/XMLSchema#string

Yung-Jue Bang

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

Repeated observation of breast tumor subtypes in independent gene expression data sets

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Hallmarks of 'BRCAness' in sporadic cancers

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

P2888

1471-2407-8-307

P304

307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-8-307

http://www.w3.org/2001/XMLSchema#string

P407

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23412132

http://www.w3.org/2001/XMLSchema#string

P6179

1015791971

http://www.w3.org/2001/XMLSchema#string

P698

18947390

http://www.w3.org/2001/XMLSchema#string

P932

2577689

http://www.w3.org/2001/XMLSchema#string